WO2004017973A1 - 統合失調症治療剤 - Google Patents
統合失調症治療剤 Download PDFInfo
- Publication number
- WO2004017973A1 WO2004017973A1 PCT/JP2003/010490 JP0310490W WO2004017973A1 WO 2004017973 A1 WO2004017973 A1 WO 2004017973A1 JP 0310490 W JP0310490 W JP 0310490W WO 2004017973 A1 WO2004017973 A1 WO 2004017973A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- schizophrenia
- active compound
- negative symptoms
- treatment method
- hydrochloride
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention relates to a new method and agent for treating schizophrenia. More specifically, the present invention relates to a method for improving schizophrenia by orally administering a predetermined amount of a specific bicycloheptanedicarboximide derivative once a day without accompanying extrapyramidal side effects. It relates to a therapeutic agent used therefor. Background art
- Schizophrenia a schizophrenia, is a type of endogenous mental illness that occurs mainly in adolescents, follows a chronic course, gradually disintegrates in personality, and some of it is devastationed.
- the symptoms include positive symptoms such as hallucinations and delusions, which are common in the early stages of the onset, as well as negative symptoms of lack of motivation and motivation, and cognitive symptoms with problems with concentration and learning.
- Treatment of this schizophrenia requires drug treatment for a long period of time, and even if healing is stopped, there is a high risk of recurrence if the drug is stopped, and drug administration is continued forever There is a need. For this reason, side effects due to drug administration become a problem, and from this viewpoint, drugs that can be administered for a long time without side effects are desired.
- Therapeutic agents for schizophrenia include various drugs classified as psychotropic drugs, for example, phenothiazine derivatives such as chlorpromazine and methoxypromazine; chlorprothixylone having a structure similar to phenothiazine, flupentixol And other drugs, such as thioxanthin derivatives, benzamide derivatives such as sulpiride and sultopride, chenodiazepine derivatives such as clothiazem and etizolam, etc. Is used.
- phenothiazine derivatives such as chlorpromazine and methoxypromazine
- chlorprothixylone having a structure similar to phenothiazine
- flupentixol And other drugs such as thioxanthin derivatives, benzamide derivatives such as sulpiride and sultopride, chenodiazepine derivatives such as clothiazem and etizolam, etc. Is used.
- phenothiazine derivatives phenothiazine analogs
- petit phenone derivatives have serious side effects such as Parkinson's disease-like symptoms in which skeletal muscles become stiff, muscles tremble, facial expressions disappear, and salivary outflow occurs.
- Diphenylbutyramine derivatives may cause insomnia and extrapyramidal syndrome.
- these existing psychotropic drugs are effective for some but not all of the positive, negative, and cognitive symptoms in schizophrenia.
- imide derivatives represented by the following general formula found by colleagues of the present inventors are used as antipsychotics (neuroleptics, anxiolytics), especially schizophrenia, senile psychosis, and manic depression It is known to be useful as a therapeutic agent for neuroses and the like (US Pat. Nos. 5,532,372).
- D has the formula :-( CH 2) p. -A- ( CH 2).
- I, G is /, or Z etc., Ar is
- the present inventors have developed a new therapeutic agent which has an excellent effect in the treatment of schizophrenia, and which can be safely administered for a long period without side effects such as extrapyramidal syndrome which is found in many conventional psychotropic drugs.
- a series of imide derivatives including their usage and dosage, we found the following formula:
- the present invention provides (1R, 2S, 3R, 4S) -N-[(lR, 2R) -2- [4- (l, 2-benzoisothiazole) represented by the above formula (1). 1 ⁇ )-1-piperazinylmethyl]-1-cyclohexylmethyl] -2,3-bicyclo [2.2. 1] Integrate a predetermined amount of heptanedicarboximide or a pharmaceutically acceptable salt thereof It is intended to provide a method for treating schizophrenia by oral administration once a day to schizophrenic patients without complication of extrapyramidal side effects, and a therapeutic agent used therefor. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 shows a double-blind clinical trial of the active compound of the present invention of (1R, 2S, 3R, 4S) -N-[(lR, 2R) -2- [4- (l, 2-Benzoisothiazole-3 1) -1-piperazinylmethyl] -1-cyclohexylmethyl-2,3-bicyclo [2.2.1] heptanedicarboximide hydrochloride integration with placebo 4 is a graph showing the change over time of the score of the Brief Psychiatric Rating Scale (BPRS), which is an index of the effect on schizophrenia.
- BPRS Brief Psychiatric Rating Scale
- the present invention relates to (1R, 2S, 3R, 4S) —N—
- the present invention also provides a novel therapeutic agent for such schizophrenia.
- the treatment method of the present invention almost no side effects such as Parkinson's disease symptoms, extrapyramidal side effects such as dyskinesia and akajijia, electrocardiogram abnormalities, abnormalities of S-dry function, etc. are observed, and the method is extremely safe. Suitable for long-term treatment.
- the active compound When applied to patients with chronic schizophrenia, it is necessary to use the above-mentioned active compound at a dose as small as possible for a long-term treatment.In such a case, one dose of the active compound is required. It is orally administered once a day in the range of 5 mg to 80 mg, preferably 5 mg to 60 mg, and more preferably 10 mg to 40 mg.
- the therapeutic agent used in the method for treating schizophrenia of the present invention is represented by the formula (1).
- Compound or a pharmaceutically acceptable salt thereof particularly (1R, 2S, 3R, 4S) —N — [(1R, 2R) —2— [4 -— (1,2-benzoisothiazol-3-yl) 1-piperazulmethyl] -1-cyclohexylmethyl] -1,2-bicyclo [2.2.1] heptandicarboximide hydrochloride in a dosage unit of 5 mg to 120 mg, preferably 1 Omg to: L 0 It is an oral preparation containing Omg, more preferably 20 mg to 80 mg. Oral preparations include tablets, granules, fine granules, powders, capsenoles, syrups and the like. These are all once-daily preparations.
- Each of the above preparations is a pharmaceutically acceptable carrier used in the preparation of ordinary pharmaceutical preparations, for example, excipients such as lactose, sucrose, glucose, starch, calcium carbonate, kaolin, talc, crystalline cellulose, caic acid, etc.
- excipients such as lactose, sucrose, glucose, starch, calcium carbonate, kaolin, talc, crystalline cellulose, caic acid, etc.
- the active compound SM-13496 used in the experimental examples was (1R, 2S, 3R, 4S) —N — [(1R, 2R) —2— [4— (1,2-ben Zosothiazol-3-inole) — 1-piperazinylmethinole] -1-1-hexyl hexylmethinole] -2,3-bisic mouth [2.2.1] heptandi force / repoxyimid hydrochloride Abbreviations in the experimental examples have the following meanings.
- DSM Diagnostic and Statistics ⁇ Manual of Mental Disorders
- CG I—S Clinical Global Impressions scale-Severity of Illness (Clinical overall impression-Disease severity)
- EPS Rating scale (Simpson-Angus, Barnes, AIMS) ⁇ Neutanore sign (temperature, blood pressure, pulse rate), 12-lead electrocardiogram, clinical test [hematological test, blood biochemical test, prolactin, urinalysis ⁇ ), psychosomatic symptoms, fundus, slit lamp microscopy, adverse events
- B PRS and PANS S scores (LOCF) and C The GI-S and CG I-I scores (LOCF) are shown in Tables 2 and 3, respectively.
- Tables 2 and 3 at the end of the study (6 weeks after administration), the amount of decrease in score before administration in the SM-13496 40 mg and 120 mg administration groups was BP RS, CG I-I and CG I
- the score reduction in the SM-13496 12 Omg group at the end of the study was statistically different from that in the placebo group. There was a significant difference, and SM-13496 improved psychiatric symptoms.
- the main adverse events were sedation, nausea, headache, akassia, dizziness (rotational dizziness) Except). Sedation was observed in 10%, 18% and 14% of the placebo and SM-13496 40 mg 12 Omg groups, respectively. Nausea was more frequent in the SM-13496 12 Omg group than in the other groups, but dyspepsia was less than in the placebo group. Schizophrenia exacerbation was less in the SM-13496 4 Omg and 12 Omg groups (4% and 2%) than in the placebo group (10%). Power sizzle was observed only in the SM-13496 administration group, and was 8% and 14% in the 40 mg and 120 mg administration groups, respectively. The incidence of adverse events in the SM-13496 group was similar to the placebo group. No weight gain, increased appetite, impotence, erectile dysfunction, or convulsions were noted.
- Pharyngolaryngeal pain 0 (0) 1 (2) 0 (0) Dyspnea 0 (0) 0 (0) 1 (2) Cardiac disorders
- the major adverse events (adverse effects) for which a causal relationship with SM-134496 can not be ruled out are sedation, nausea, akassia, floating dizziness (excluding vertigo) ), Somnolence, headache.
- the incidence of dystonia was low ( ⁇ 4%) in the SM-134496 group.
- No clinically significant changes were observed in the 12-lead ECG.
- Moderate increase in blood prolactin was observed in the SM-; I3496 group, but no clinically significant findings were found in body temperature, respiratory rate, fundus examination, or slit lamp microscopy .
- Table 8 shows the results of evaluation of extrapyramidal symptoms of dyskinesia (by AIMS), akashijia (by BAS), and Parkinson-like symptoms (by SAS).
- the method for treating schizophrenia of the present invention and the therapeutic agent used therefor include the active compound (1R, 2S, 3R, 4S) -N-[(lR, 2R) -2— [4 1- (1,2-benzisothiazol-3-inole) 1 1-piperazinylmethinole]-1-cyclohexinolemethinole]-
- Oral administration of 2,3-bicyclo [2.2.1] heptanedicarboximide or a pharmaceutically acceptable salt thereof, particularly a predetermined amount of a hydrochloride, to a schizophrenic patient once a day, can be performed by oral administration. It is effective in improving a wide range of schizophrenia including positive, negative, and cognitive symptoms without complicating extracorporeal side effects, and is particularly effective in improving positive and negative symptoms. It is an extremely excellent treatment method and agent because it is extremely safe to apply, has no sedative effect, is suitable for long-term administration, and can be used safely by elderly people.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60327634T DE60327634D1 (de) | 2002-08-22 | 2003-08-20 | Mittel zur behandlung des integrationsdysfunktionssyndroms |
US10/525,021 US9174975B2 (en) | 2002-08-22 | 2003-08-20 | Remedy for integration dysfunction syndrome |
AT03792731T ATE431147T1 (de) | 2002-08-22 | 2003-08-20 | Mittel zur behandlung des integrationsdysfunktionssyndroms |
JP2004530573A JP4745661B2 (ja) | 2002-08-22 | 2003-08-20 | 統合失調症治療剤 |
EP03792731A EP1535616B1 (en) | 2002-08-22 | 2003-08-20 | Remedy for integration dysfunction syndrome |
EP08153777.1A EP1944030B1 (en) | 2002-08-22 | 2003-08-20 | Agent for treatment of schizophrenia |
AU2003257589A AU2003257589A1 (en) | 2002-08-22 | 2003-08-20 | Remedy for integration dysfunction syndrome |
US14/471,919 US9815827B2 (en) | 2002-08-22 | 2014-08-28 | Agent for treatment of schizophrenia |
US15/726,907 US20180051017A1 (en) | 2002-08-22 | 2017-10-06 | Agent for treatment of schizophrenia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40492702P | 2002-08-22 | 2002-08-22 | |
US60/404,927 | 2002-08-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/525,021 A-371-Of-International US9174975B2 (en) | 2002-08-22 | 2003-08-20 | Remedy for integration dysfunction syndrome |
US14/471,919 Continuation US9815827B2 (en) | 2002-08-22 | 2014-08-28 | Agent for treatment of schizophrenia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004017973A1 true WO2004017973A1 (ja) | 2004-03-04 |
Family
ID=31946785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/010490 WO2004017973A1 (ja) | 2002-08-22 | 2003-08-20 | 統合失調症治療剤 |
Country Status (8)
Country | Link |
---|---|
US (3) | US9174975B2 (ja) |
EP (3) | EP2295061A1 (ja) |
JP (1) | JP4745661B2 (ja) |
AT (1) | ATE431147T1 (ja) |
AU (1) | AU2003257589A1 (ja) |
DE (1) | DE60327634D1 (ja) |
ES (2) | ES2685780T3 (ja) |
WO (1) | WO2004017973A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011093522A1 (en) * | 2010-01-28 | 2011-08-04 | Dainippon Sumitomo Pharma Co., Ltd. | A cycloalkane derivative |
WO2012063513A1 (en) * | 2010-11-08 | 2012-05-18 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
US8552000B2 (en) | 2003-06-23 | 2013-10-08 | Dainippon Sumitomo Pharma Co., Ltd. | Therapeutic agent for senile dementia |
US8835438B2 (en) | 2004-02-20 | 2014-09-16 | Sumitomo Dainippon Pharma Co., Ltd. | Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone |
US20150056284A1 (en) * | 2005-05-26 | 2015-02-26 | Sumitomo Dainippon Pharma Co., Ltd | Pharmaceutical composition |
US9174975B2 (en) | 2002-08-22 | 2015-11-03 | Sumitomo Dainippon Pharma Co., Ltd | Remedy for integration dysfunction syndrome |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2785347A1 (en) * | 2011-12-02 | 2014-10-08 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone novel dosage regimens and use thereof for the treatment, prevention, and/or management of at least one cns disorder |
SI3154967T1 (sl) | 2014-06-16 | 2020-11-30 | Johnson Matthey Public Limited Company, | Postopki za pripravo alkiliranih arilpiperazinskih in alkiliranih arilpiperidinskih spojin, ki vključujejo nove intermediate |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464846A1 (en) * | 1990-07-06 | 1992-01-08 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives, and their production and use |
WO2002024166A1 (fr) * | 2000-09-22 | 2002-03-28 | Sumitomo Pharmaceuticals Company, Limited | Preparations orales dotees de bonnes caracteristiques de desagregation |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0464846A (ja) * | 1990-07-05 | 1992-02-28 | Matsushita Seiko Co Ltd | Oa機器用フード装置 |
JP3211279B2 (ja) * | 1990-10-08 | 2001-09-25 | 住友化学工業株式会社 | 高純度カルボン酸フェニルエステル類の製造方法 |
DK36291D0 (da) | 1991-03-01 | 1991-03-01 | Lundbeck & Co As H | Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser |
GB9202915D0 (en) | 1992-02-12 | 1992-03-25 | Wellcome Found | Chemical compounds |
IL110011A (en) | 1994-06-13 | 2004-09-27 | Yeda Res & Dev | Pharmacological preparations for the treatment of schizophrenia |
WO1996014297A1 (fr) | 1994-11-04 | 1996-05-17 | Sumitomo Pharmaceuticals Company, Limited | Nouveaux derives de lactame |
JP3775823B2 (ja) | 1995-06-09 | 2006-05-17 | 大日本住友製薬株式会社 | 新規なイミド誘導体 |
ATE369848T1 (de) * | 1998-04-14 | 2007-09-15 | Gen Hospital Corp | Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie |
AU3783799A (en) * | 1998-05-05 | 1999-11-23 | Jose Pozuelo | Compositions and methods for treating particular chemical addictions and mental illnesses |
JP2000281576A (ja) | 1999-03-29 | 2000-10-10 | Sumitomo Pharmaceut Co Ltd | イミド誘導体を含有するプロテオグリカン生成促進剤 |
AR027134A1 (es) | 1999-12-30 | 2003-03-12 | Lundbeck & Co As H | Derivados de indol. |
US20020082283A1 (en) | 2000-09-14 | 2002-06-27 | Gliatech, Inc. | Nitrogen-containing compounds and their use as glycine transport inhibitors |
WO2002053140A2 (en) * | 2001-01-02 | 2002-07-11 | Pharmacia & Upjohn Company | New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents |
EP1378492B1 (en) * | 2001-02-21 | 2008-04-02 | Seiwa Pro Co., Ltd. | Remover for scale deposited on titanium material |
WO2002100399A1 (en) | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
JP4568463B2 (ja) | 2001-11-05 | 2010-10-27 | 独立行政法人科学技術振興機構 | ドレブリンa発現抑制動物神経細胞及び非ヒトモデル動物 |
JP4175800B2 (ja) | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | イミド誘導体の製造方法 |
WO2003066039A1 (en) * | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
WO2004017973A1 (ja) | 2002-08-22 | 2004-03-04 | Sumitomo Pharmaceuticals Company, Limited | 統合失調症治療剤 |
WO2004113333A1 (ja) | 2003-06-23 | 2004-12-29 | Dainippon Sumitomo Pharma Co., Ltd. | 老人性痴呆症治療剤 |
EP2357474A1 (en) | 2004-02-20 | 2011-08-17 | Dainippon Sumitomo Pharma Co., Ltd. | Lurasidone for use in the treatment of memory or learning dysfunction by schizophrenia |
US7122683B2 (en) | 2004-11-23 | 2006-10-17 | Pfizer Inc. | Amides useful as monoamine re-uptake inhibitors |
TW200812993A (en) | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
WO2008054793A2 (en) | 2006-10-30 | 2008-05-08 | Sanrx Pharmaceuticals, Inc. | Dipterinyl calcium pentahydrate (dcp) and therapeutic methods based thereon |
PT2144905E (pt) | 2007-04-04 | 2013-02-26 | Merck Sharp & Dohme | Agentes terapêuticos |
-
2003
- 2003-08-20 WO PCT/JP2003/010490 patent/WO2004017973A1/ja active Application Filing
- 2003-08-20 AU AU2003257589A patent/AU2003257589A1/en not_active Abandoned
- 2003-08-20 AT AT03792731T patent/ATE431147T1/de active
- 2003-08-20 EP EP10013201A patent/EP2295061A1/en not_active Withdrawn
- 2003-08-20 ES ES08153777.1T patent/ES2685780T3/es not_active Expired - Lifetime
- 2003-08-20 DE DE60327634T patent/DE60327634D1/de not_active Expired - Lifetime
- 2003-08-20 JP JP2004530573A patent/JP4745661B2/ja not_active Expired - Lifetime
- 2003-08-20 ES ES03792731T patent/ES2326078T3/es not_active Expired - Lifetime
- 2003-08-20 EP EP08153777.1A patent/EP1944030B1/en not_active Expired - Lifetime
- 2003-08-20 EP EP03792731A patent/EP1535616B1/en not_active Expired - Lifetime
- 2003-08-20 US US10/525,021 patent/US9174975B2/en active Active
-
2014
- 2014-08-28 US US14/471,919 patent/US9815827B2/en not_active Expired - Lifetime
-
2017
- 2017-10-06 US US15/726,907 patent/US20180051017A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0464846A1 (en) * | 1990-07-06 | 1992-01-08 | Sumitomo Pharmaceuticals Company, Limited | Imide derivatives, and their production and use |
WO2002024166A1 (fr) * | 2000-09-22 | 2002-03-28 | Sumitomo Pharmaceuticals Company, Limited | Preparations orales dotees de bonnes caracteristiques de desagregation |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9815827B2 (en) | 2002-08-22 | 2017-11-14 | Sumitomo Dainippon Pharma Co., Ltd. | Agent for treatment of schizophrenia |
US9174975B2 (en) | 2002-08-22 | 2015-11-03 | Sumitomo Dainippon Pharma Co., Ltd | Remedy for integration dysfunction syndrome |
US8552000B2 (en) | 2003-06-23 | 2013-10-08 | Dainippon Sumitomo Pharma Co., Ltd. | Therapeutic agent for senile dementia |
US8835438B2 (en) | 2004-02-20 | 2014-09-16 | Sumitomo Dainippon Pharma Co., Ltd. | Method of treating memory/learning dysfunctions caused by schizophrenia with lurasidone |
US20150056284A1 (en) * | 2005-05-26 | 2015-02-26 | Sumitomo Dainippon Pharma Co., Ltd | Pharmaceutical composition |
US20150265611A1 (en) * | 2005-05-26 | 2015-09-24 | Sumitomo Dainippon Pharma Co., Ltd | Pharmaceutical composition |
US9555027B2 (en) * | 2005-05-26 | 2017-01-31 | Sumitomo Dainippon Pharma Co., Ltd. | Pharmaceutical composition |
US9907794B2 (en) | 2005-05-26 | 2018-03-06 | Sumitomo Dainippon Pharma Co., Ltd | Pharmaceutical composition |
WO2011093522A1 (en) * | 2010-01-28 | 2011-08-04 | Dainippon Sumitomo Pharma Co., Ltd. | A cycloalkane derivative |
US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
WO2012063513A1 (en) * | 2010-11-08 | 2012-05-18 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
JP2013541582A (ja) * | 2010-11-08 | 2013-11-14 | 大日本住友製薬株式会社 | 精神疾患の治療方法 |
US9259423B2 (en) | 2010-11-08 | 2016-02-16 | Sumitomo Dainippon Pharma Co., Ltd. | Method of treatment for mental disorders |
JP2016094440A (ja) * | 2010-11-08 | 2016-05-26 | 大日本住友製薬株式会社 | 精神疾患の治療方法 |
US9827242B2 (en) | 2010-11-08 | 2017-11-28 | Sumitomo Dainippon Pharma Co., Ltd. | Method of treatment for mental disorders |
US10098875B2 (en) | 2010-11-08 | 2018-10-16 | Sumitomo Dainippon Pharma Co., Ltd. | Method of treatment for mental disorders |
Also Published As
Publication number | Publication date |
---|---|
US20060025422A1 (en) | 2006-02-02 |
US20180051017A1 (en) | 2018-02-22 |
US20140371236A1 (en) | 2014-12-18 |
AU2003257589A1 (en) | 2004-03-11 |
JP4745661B2 (ja) | 2011-08-10 |
US9815827B2 (en) | 2017-11-14 |
EP1535616A1 (en) | 2005-06-01 |
EP1535616A4 (en) | 2005-11-30 |
JPWO2004017973A1 (ja) | 2005-12-08 |
ES2685780T3 (es) | 2018-10-11 |
EP2295061A1 (en) | 2011-03-16 |
EP1944030A1 (en) | 2008-07-16 |
EP1535616B1 (en) | 2009-05-13 |
US9174975B2 (en) | 2015-11-03 |
EP1944030B1 (en) | 2018-08-01 |
DE60327634D1 (de) | 2009-06-25 |
ATE431147T1 (de) | 2009-05-15 |
ES2326078T3 (es) | 2009-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9815827B2 (en) | Agent for treatment of schizophrenia | |
JPH0667841B2 (ja) | 恐慌障害の軽減剤 | |
JP2016138142A (ja) | 大うつ病を有する患者において減量療法を提供する方法 | |
JP2010513250A5 (ja) | ||
CN112870195A (zh) | 骨质疏松症治疗剂 | |
RU2004131214A (ru) | Способы лечения когнитивных расстройств | |
US4882345A (en) | Use of a compound for the treatment of schizophrenia | |
JP5566521B1 (ja) | 膀胱・尿道協調不全改善剤 | |
JP6328856B2 (ja) | 収縮力低下随伴性排尿筋過活動改善剤 | |
JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
JP2018177773A (ja) | 医薬 | |
JP7312286B2 (ja) | うつ病を予防または治療するための安息香酸またはその塩および誘導体 | |
Hoang et al. | Zinc Iodide-Dimethyl Sulfoxide Composition in Treatment of Chronic Respiratory Diseases | |
JP6032681B2 (ja) | 排尿障害の予防・治療剤 | |
JPWO2005027968A1 (ja) | ダウン症候群治療剤 | |
JP2006036712A (ja) | 脳梗塞予防または治療薬としてのビトロネクチン拮抗物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004530573 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2006025422 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10525021 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003792731 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003792731 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10525021 Country of ref document: US |